Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Allergan, Ideal Implant Issued Warning Letters From FDA Related to Breast Implants

share with twitter share with LinkedIn share with facebook
05/14/2020 | 05:34pm EDT

By Allison Prang

Allergan and Ideal Implant Inc., manufacturers of breast implants, were issued warning letters from the U.S. Food and Drug Administration, the regulator said, for not complying with regulations.

The FDA said Allergan, which is now owned by AbbVie, didn't do post-approval studies to evaluate the risks and safety on a long-term basis for two implant models. The implants were recalled last year, the FDA said.

The regulator said its letter to the company mentioned "several serious deficiencies in the manufacturer's post-approval study" for two types of implants: its Round Responsive implants and Style 410 implants.

Ideal Implant didn't meet "good manufacturing practice requirements and adverse event reporting requirements," the FDA said.

The FDA's letter to Ideal Implant pointed out that the company didn't keep "proper files for device complaints," and also didn't have "appropriate procedures for implementing corrective and preventive actions." The regulator said the company didn't "maintain adequate criteria for testing finished devices."

The regulator asked both companies to respond within 15 workdays of being issued the its letters.


Write to Allison Prang at allison.prang@wsj.com


Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 0.04% 84.34 Delayed Quote.-4.74%
ALLERGAN PLC 0.02% 193.02 Delayed Quote.0.97%
BYD COMPANY LIMITED -6.66% 135.9 End-of-day quote.249.81%
THE NEW HOME COMPANY INC. 0.60% 5.06 Delayed Quote.8.58%
share with twitter share with LinkedIn share with facebook
All news about ABBVIE INC.
10/19ABBVIE : Seeks U.S., European OK of Rinvoq in Eczema
10/19ABBVIE : VENCLEXTA Receives FDA Full Approval for Acute Myeloid Leukemia
10/19ABBVIE : Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upada..
10/19ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
10/19ABBVIE : Announces Commencement of Registered Exchange Offers
10/16NEWS HIGHLIGHTS : Top Company News of the Day
10/16NEWS HIGHLIGHTS : Top Company News of the Day
10/16NIH to Study Three Drugs in Treatment of Covid-19 Patients
10/14ABBVIE INC. : Ex-dividend day for
10/13NIH starts clinical trial testing antibody treatments in COVID-19 patients
More news
Financials (USD)
Sales 2020 45 372 M - -
Net income 2020 9 839 M - -
Net Debt 2020 74 016 M - -
P/E ratio 2020 16,5x
Yield 2020 5,85%
Capitalization 149 B 149 B -
EV / Sales 2020 4,91x
EV / Sales 2021 3,98x
Nbr of Employees 47 000
Free-Float 98,5%
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 20
Average target price 109,25 $
Last Close Price 84,34 $
Spread / Highest target 50,6%
Spread / Average Target 29,5%
Spread / Lowest Target 13,8%
EPS Revisions
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.-4.74%148 846
JOHNSON & JOHNSON-0.43%382 350
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999